Literature DB >> 28850731

The role of β-blockers in dermatological treatment: a review.

L Chen1, T-F Tsai2.   

Abstract

Many systemic medications have been used off-label in cutaneous diseases. Use of β-adrenergic-blocking agents has risen in popularity among dermatologists since the discovery of their efficacy in treating infantile haemangioma. There has also been an increase in the interest of the applications of β-blockers in other skin disorders. Overall, β-blockers are effective in treating diseases of vascular origin and promote wound healing. They are relatively safe and inexpensive medications that could be included in the armamentarium against skin diseases.
© 2017 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28850731     DOI: 10.1111/jdv.14566

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  4 in total

Review 1.  The Role of β-Blockers in Melanoma.

Authors:  Vincenzo De Giorgi; Pierangelo Geppetti; Chiara Lupi; Silvia Benemei
Journal:  J Neuroimmune Pharmacol       Date:  2019-09-03       Impact factor: 4.147

2.  Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds.

Authors:  Anthony Cole Gallegos; Michael James Davis; Catherine N Tchanque-Fossuo; Kaitlyn West; Angela Eisentrout-Melton; Thomas R Peavy; Roy W Dixon; Roma P Patel; Sara Evona Dahle; Roslyn Rivkah Isseroff
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-10-16       Impact factor: 4.730

Review 3.  Repurposing Ophthalmologic Timolol for Dermatologic Use: Caveats and Historical Review of Adverse Events.

Authors:  Daniel J Yoon; Ramanjot Kaur; Anthony Gallegos; Kaitlyn West; Hsinya Yang; Saul Schaefer; Catherine Tchanque-Fossuo; Sara E Dahle; R Rivkah Isseroff
Journal:  Am J Clin Dermatol       Date:  2020-11-25       Impact factor: 7.403

4.  Alpha and beta adrenergic receptors modulate keratinocyte migration.

Authors:  Hsin-Ya Yang; Pieter Steenhuis; Aaron M Glucksman; Zhanna Gurenko; Thi Dinh La; R Rivkah Isseroff
Journal:  PLoS One       Date:  2021-07-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.